Jump to content

AstraZeneca share price rebounds following FY21 results update


MongiIG

Recommended Posts

In this article we review the AstraZeneca results and how the share price has reacted to the news.

bg_astrazeneca_336609093.jpgSource: Bloomberg
 Shaun Murison | Senior Market Analyst, Johannesburg | Publication date: Thursday 10 February 2022 

AstraZeneca's fourth quarter (Q4) and full-year (FY) results have seen the group’s share price bucking the short-term sector trend as of late as it gains on the news.

A summary of the results is as follows:

  • Total revenue for the year increased by 41% to $37,417 million including COVID-19 vaccine revenues
  • Total Revenue for the year, excluding vaccines, increased 26% to $33,436m
  • Reported earnings per share (EPS) of $0.08 in FY21 vs $2.44 in FY20
  • Core EPS of $5.29 in FY21 vs $4.02 in FY20

FY22 outlook

AstraZeneca has provided the following in terms of the new financial year's outlook:

  • The majority of vaccine revenue in 2022 is expected to come from initial contracts
  • The Gross Profit Margin from the COVID-19 medicines is expected to be lower than the company average
  • Core Operating Expenses are expected to increase by a low-to-mid teens percentage, driven in substantial part by the full-year integration of Alexion expenses
  • Emerging Markets Total Revenue, including China, is expected to grow mid-single digits in FY 2022
  • China Total Revenue is expected to decline by a mid-single digit percentage in FY 2022, primarily due to continued NRDL and VBP programme impacting various medicines
  • The company remains confident in the longer term outlook for Emerging Markets, driven by a large market opportunity, broader patient access and an increased mix of new medicines

Comments on results

Double-digit growth across all of the group’s major jurisdictions, combined with the Alexion acquisition, has seen strong revenue growth for the group.

The reported drop in EPS (97%) reflects items related to the acquisition of Alexion, amortisation of intangibles, as well as impairments and restructuring charges.

The Core EPS figure, which omits the one-off items, highlights growth of around 32% in the group's primary operations.

While future earnings growth from COVID-19 products is expected to slow, the group is perhaps less reliant on these products than its peers, Pfizer and Moderna as a proportion of income and future growth.

Astrazeneca – technical analysis

AZ%201002.pngSource: IG charts

 

The share price of AstraZeneca has formed a sharp bullish price reversal near the 8120 level and from oversold territory. The reversal suggests 8860 and 8960 respectively as upside resistance targets from the move.

Traders looking to go long might consider using a close below 8120 as a stop-loss indication for the trade, although will need to assess whether the risk-to-reward is a favourable enough opportunity for the position.

Link to comment

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
  • image.png

  • Posts

    • With the CryptoSpace evolving everydayy, a plethora of ways also trump up for users to earn and have fun alongside. Some of these events are my favourites. I have participated in a couple of them and the potential to earn therefrom is immense.  Just recently, I came across an event on Bitget for its users to earn passively as well as an opportunity to spin the wheel to win an all expense tour to Santorini island. The criteria for participating in this is relatively simple, you just need to make a net deposit of over 100 USDT and maintain the amount for a day. Depositing greater sums like $500 USDT, 1000 USDT and 1 BTC can further your chances of winning. The more tasks completed, the more spins a participant may have. The event is exclusively restricted to users from the; United Kingdom, Canada, Australia/DACH, French, Italian, Netherlands, Sweden and Poland region. The total prize pool is $50,000 based on FCFS serve basis. This sounds too good to look away from.
    • Still the silence is deafening in here. When will this happen?  it have moved most my Trading Capital to another broker who does support Trading veiw Does the deal with Tastytrade have something to do with this lack of progress?  
    • Well to me I feel that the  crypto market values transparency and reliable services. And Bitget has embraced this approach, attracting a large following,gaining up to 1.4million twitter followers,. Recent data shows significant growth in trading volume, solidifying its position in the market.  The exchanges  focus on user protection and satisfaction has fostered a loyal community. As the platform continues to evolve, its value may continue to grow. What are your thoughts on the importance of value in crypto, and what do you see as Bitget's future potential?
×
×
  • Create New...
us